by Peter Ciszewski | Jul 21, 2021
Tarun Kumar Bansal, President at Sagacious IP, discusses Refer4Rare, a database that includes all relevant IP information for rare disease researchers and developers. Sagacious IP is an intellectual property research & consulting firm specializing in IP...
by Peter Ciszewski | Jul 14, 2021
Paula Ragan, PhD, CEO and President, X4 Pharmaceuticals, gives an overview of Waldenström’s Macroglobulinemia (WM). As Dr. Ragan explains, WM is a rare blood cancer and a type of non-Hodgkin’s lymphoma which causes an overproduction of immunoglobulin M (IgM)....
by Peter Ciszewski | Jul 13, 2021
Heather Olson, MD, MS, Neurologist at Boston Children’s and Neurology Instructor at Harvard Medical, gives an overview of FOXG1 syndrome. FOXG1 syndrome is a neurological condition characterized by impaired development and structural brain abnormalities....
by Peter Ciszewski | Jul 9, 2021
Paula Ragan, PhD, CEO and President, X4 Pharmaceuticals, discusses positive interim data from the phase 1b clinical trial (NCT04274738) evaluating mavorixafor in combination with ibrutinib in double-mutation Waldenström’s Macroglobulinemia (WM) patients. WM is...
by Peter Ciszewski | Jul 8, 2021
Heather Olson, MD, MS, Neurologist at Boston Children’s and Neurology Instructor at Harvard Medical, discusses FOXG1 Research Foundation’s Natural History Study. FOXG1 syndrome is a neurological condition characterized by impaired development and...
